Dr. Jeanne Marrazzo was appointed by the National Institutes of Health on Wednesday to serve as the new director of the National Institute of Allergy and Infectious Diseases. According to the NIH, Marrazzo is scheduled to start her new job in the fall. She takes over from Dr. Hugh Auchincloss Jr., who has held the position of director in temporary capacity since Dr. Anthony Fauci left the position in December.
At the University of Alabama in Birmingham, Marrazzo oversees the division of infectious diseases. NIAID is the second-largest center of the NIH, after the National Cancer Institute, with a $6.3 billion budget. It encourages study that will improve our knowledge of infectious, immunologic, and allergy disorders as well as their diagnosis and treatment. The institute was instrumental in the creation of ground-breaking vaccines and the nation’s reaction to the Covid-19 pandemic.
Along with a nationwide network of 21 NIAID labs, the NIAID funds research initiatives at universities and research institutions throughout the United States. Along with a nationwide network of 21 NIAID labs, the NIAID funds research initiatives at universities and research institutions throughout the United States. Fauci expressed his happiness with Marrazzo’s appointment to his previous position on Wednesday. After nearly four decades as the director of NIAID, Fauci, 82, retired in December. He has since joined the Georgetown University faculty.
“She is a very admirable individual. She’s going to perform admirably, in my opinion. Therefore, I’m actually extremely happy with the decision,” he said. Fauci noted that the journey would not be simple. Fauci stated that he did not have the opportunity to speak with Marrazzo and that he first learned of her nomination on Tuesday. He claimed that if counsel was sought, he would advise her to stay with the science.
Dr. Marrazzo’s Noteworthy Contributions to HIV Prevention and STD Research
Marrazzo is most renowned for her work in the field of HIV prevention among other STDs. Marrazzo oversaw a sizable trial in Africa from 2009 to 2011 that examined the effectiveness of vaginally and orally administered drugs for preventing HIV in women before pre-exposure. 2015 saw the study’s publication in the New England Journal of Medicine. Dr. Carlos del Rio, president of the Infectious Diseases Society of America, or IDSA, called her a remarkable doctor, researcher, and advocate.
She has a lengthy history of working to prevent HIV and sexually transmitted illnesses. She also has a wonderful attitude, is a fantastic listener, and is a lovely person. To be honest, I’m just ecstatic.
Del Rio, who meets with Marrazzo frequently because she also serves on the IDSA Board of Directors, stated that she is a superb candidate for the position. Marrazzo, according to Del Rio, is anxious to start working at NIAID and enjoys traveling and bird watching in her spare time.